Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1.

Authors :: Yasuda KI
Nobeyama Y
Ishiji T
Ota A
Asahina A
Source :: Clinical case reports [Clin Case Rep] 2020 Jun 26; Vol. 8 (11), pp. 2125-2128. Date of Electronic Publication: 2020 Jun 26 (Print Publication: 2020).
Publication Year :: 2020
Abstract: Imatinib mesylate seemed to inhibit development of cutaneous neurofibromas (c-NFs) and promote growth of pre-existing c-NFs in our neurofibromatosis type 1 case. This report potentially provides new findings in the effects of imatinib mesylate.<br />Competing Interests: The authors have no conflicts of interest to declare.<br /> (© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)

Full Text Access

Tools